Granted Patent
B2
US 12,473,348 · App. 17/356,423 · Granted Nov 18, 2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
Inventors:
Hans G. Klingemann (Culver City, CA); Laurent H. Boissel (Culver City, CA); Abhijit Dandapat (Culver City, CA)
Assignee:
ImmunityBio, Inc.
C07K14/70535A61K40/15A61K40/30A61K40/31A61K40/35A61K40/4224A61P35/04C07K14/5443C07K14/55C07K14/7051C07K16/2827C12N5/0646
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.
Claims (20)
1 . A plurality of recombinant NK-92 cells that each express an anti-PD-L1 chimeric antigen receptor (CAR) and an Fc receptor,
wherein the NK-92 cell specifically targets a PDL-1 expressing cell, and wherein the PD-L1 expressing cell is a myeloid-derived suppressor cell (MDSC) or a tumor associated macrophage (TAM),
wherein the CAR has at least 90% sequence identity to SEQ ID NO:15.
2 . The plurality of claim 1 , wherein each recombinant NK-92 cell further expresses an endoplasmic reticulum-retained IL-2 (erIL-2).
3 . The plurality of claim 2 , wherein the erIL-2 comprises SEQ ID NO:7.
4 . The plurality of claim 3 , wherein the CAR has at least 95% sequence identity to SEQ ID NO:15.
5 . The plurality of claim 4 , wherein the CAR has at least 99% sequence identity to SEQ ID NO:15.
6 . The plurality of claim 1 , wherein the CAR has the amino acid sequence of SEQ ID NO:15.
7 . The plurality of claim 6 , wherein the Fc receptor has the amino acid sequence of SEQ ID NO:2.
8 . The plurality of claim 7 , wherein each recombinant NK-92 cell comprises a tricistronic nucleic acid.
9 . The plurality of claim 8 , wherein the tricistronic nucleic acid has the sequence of SEQ ID NO:11.
10 . The plurality of claim 9 , further comprising an antibody.
11 . The plurality of claim 9 , wherein the CAR has the amino acid sequence of SEQ ID NO:15.
12 . The plurality of claim 11 , wherein the erIL-2 has the amino acid sequence of consists of SEQ ID NO:7.
13 . The plurality of claim 12 , wherein the Fc receptor has the amino acid sequence of SEQ ID NO:2.
14 . The plurality of claim 13 , further comprising an antibody.
15 . The plurality of claim 13 , wherein the plurality is in a tumor microenvironment.
16 . The plurality of claim 14 , wherein the plurality is in a tumor microenvironment.
17 . The plurality of claim 9 , wherein the plurality is in a tumor microenvironment.
18 . The plurality of claim 1 , wherein the plurality is in a tumor microenvironment.
Assignments (3)
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
CHANGE OF NAME
Recorded Aug 18, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057220/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 11, 2021
From: DANDAPAT, ABHIJIT; KLINGEMANN, HANS G.; BOISSEL, LAURENT H.
To: NANTKWEST, INC.
Reel/Frame 057148/0053 →
Continuity (3)
Provisional Application
62753740
· Oct 31, 2018
References Cited (90)
US 7618817B2
· Campbell
· 2009
[cited by applicant]
US 8034332B2
· Klingemann
· 2011
[cited by applicant]
US 8313943B2
· Campbell
· 2012
[cited by applicant]
US 9150636B2
· Campbell
· 2015
[cited by applicant]
US 9181322B2
· Campbell
· 2015
[cited by applicant]
US 20020068044A1
· Klingemann
· 2002
[cited by applicant]
US 20130040386A1
· Campbell
· 2013
[cited by applicant]
US 20180002424A1
· Belk et al.
· 2018
[cited by applicant]
US 20180193383A1
· Lee et al.
· 2018
[cited by applicant]
AU 2019370094A1
· 2020
[cited by applicant]
AU 2019370094B2
· 2022
[cited by applicant]
CA 3094111A1
· 2020
[cited by applicant]
CN 107384870A
· 2017
[cited by applicant]
CN 107709552A
· 2018
[cited by applicant]
CN 112567024A
· 2021
[cited by applicant]
JP 2021519602A
· 2021
[cited by applicant]
KR 20170131569A
· 2017
[cited by applicant]
KR 1020200119891A
· 2020
[cited by applicant]
WO 9849268A1
· 1998
[cited by applicant]
WO WO2006004518A1
· 2006
[cited by examiner]
WO 2016160602A2
· 2016
[cited by applicant]
WO 2016201304A1
· 2016
[cited by applicant]
WO 2017080377A1
· 2017
[cited by applicant]
WO 2017100709A1
· 2017
[cited by applicant]
WO 2018013975A1
· 2018
[cited by applicant]
WO 2018075989A1
· 2018
[cited by applicant]
WO 2018076391A1
· 2018
[cited by applicant]
WO 2018096391A1
· 2018
[cited by applicant]
WO WO2019152513A1
· 2019
[cited by examiner]
WO 2019226708A1
· 2019
[cited by applicant]
WO 2020028656A1
· 2020
[cited by applicant]
WO 2020091868A1
· 2020
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2020556309 dated Nov. 2, 2021, 4 pages.(Including English Translation).
[cited by applicant]
Zhang et al., “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”, Journal of Immunology Research, 2018, vol. 2018, No. 4263520, 11 pages.
[cited by applicant]
Tang et al., “First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia”, American Journal Cancer Research, 2018, vol. 8, No. 6, …
[cited by applicant]
Notice of Allowance received for KR Patent Application Serial No. 10-2020-7028887 dated Mar. 20, 2023, 12 pages. (Including English Translation).
[cited by applicant]
Office Action received for KR Patent Application Serial No. 10-2020-7028887 dated Aug. 17, 2022, 08 pages. (Including English Translation).
[cited by applicant]
Office Action received for KR Patent Application Serial No. 10-2023-7015968 dated Jun. 19, 2023, 07 pages. (Including English Translation).
[cited by applicant]
Decision of Grant received for JP Patent Application Serial No. 2020-556309 dated May 10, 2022, 08 pages. (Including English Translation).
[cited by applicant]
Office Action received for JP Patent Application Serial No. 2022-093726 dated Jul. 4, 2023, 12 pages. (Including English Translation).
[cited by applicant]
Office Action received for JP Patent Application Serial No. 2022-093726 dated Jul. 4, 2023, 07 pages. (Including English Translation).
[cited by applicant]
Office Action received for IL Patent Application Serial No. 277386 dated May 4, 2022, 04 pages. (Including English Translation).
[cited by applicant]
Notice of Acceptance received for IL Patent Application Serial No. 277386 dated Oct. 2, 2022, 06 pages. (Including English Translation).
[cited by applicant]
Office Action received for IL Patent Application Serial No. 296408 dated Apr. 4, 2023, 08 pages. (Including English Translation).
[cited by applicant]
First Exam Report received for AU Patent Application Serial No. 2022203822 dated Feb. 7, 2024, 03 pages.
[cited by applicant]
Second Exam Report received for CA Patent Application Serial No. 3,094,111 dated Aug. 29, 2022, 03 pages.
[cited by applicant]
Notice of Acceptance received for AU Patent Application Serial No. 2019370094 dated Jan. 20, 2022, 03 pages.
[cited by applicant]
Notice of Allowance received for CA Patent Application Serial No. 3,094,111 dated Sep. 20, 2023, 01 page.
[cited by applicant]
First office Action received for CN application serial No. 201980023745.0 dated Aug. 29, 2023, 15 pages (including English Translation).
[cited by applicant]
First Examination Report received for Israel Patent Application Serial No. 277386 dated Nov. 28, 2021, 15 pages. (Including English Translation).
[cited by applicant]
Examination Report No. 1 received for Australian Patent Application Serial No. 2019370094 dated Nov. 23, 2021, 3 pages.
[cited by applicant]
Office Action received for Korean Patent Application No. 10-2023-7015968 dated Dec. 14, 2023, 8 pages (including English translation).
[cited by applicant]
Office Action received for Japan Patent Application No. 2022-093726 dated Jan. 5, 2024, 07 pages (including English translation).
[cited by applicant]
Office Action received for Japan Patent Application No. 2022-093726 dated Aug. 2, 2024, 08 pages (including English translation).
[cited by applicant]
Office Action received for CN Application serial No. 201980023745.0 dated Jun. 20, 2024, 13 pages (including English translation).
[cited by applicant]
Extended European Search Report received for European Patent Application Serial No. 19877980.3 dated Oct. 28, 2021, 11 pages.
[cited by applicant]
Hodson Jen, “NantKwest Launches First-in-Class, First-in-Human Phase I Clinical Trial With a Targeted PD-L 1 t-haNK Cell Therapy in Patients with Solid Tumors”, Internet webpage, NantKwest, URL: https://nantkwest.com/na…
[cited by applicant]
Jochems et al., “ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody”, International journal of cancer, 2017, vol. 141, pp. 583-593.
[cited by applicant]
Morvan et al., “NK cells and cancer: you can teach innate cells new tricks”, Nature Reviews Cancer, 2016, vol. 16, pp. 7-19.
[cited by applicant]
Boyerinas et al. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L 1 antibody, avelumab (MSB0010718C), on human tumor cells Cancer Immunol. Res. 3, 1148-1157.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/529,159 dated Mar. 23, 2020, 29 pages.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/529,159 dated Nov. 9, 2020, 21 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,159 dated Mar. 17, 2021, 13 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,159 dated Jul. 14, 2020, 18 pages.
[cited by applicant]
International Preliminary Report on Patentability Chapter I received for PCT Application Serial No. PCT/US2019/044637 Dated May 14, 2021, 8 Pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/529,159 dated May 21, 2021, 20pages.
[cited by applicant]
Swartz et al., “Tumor micro environment complexity: emerging roles in cancer therapy”, Cancer Research, 2012, vol. 72, No. 10, pp. 2473-2480.
[cited by applicant]
Herberman et al., “Natural killer cells: their roles in defenses against disease”, Science, 1981, vol. 214, pp. 24-30.
[cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”, Leukemia, 1994, vol. 8, No. 4, pp. 652-658.
[cited by applicant]
Bronte et al., “Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards”, Nature Communications, 2016, vol. 7, No. 12150, pp. 1-10.
[cited by applicant]
Eksioglu et al., “Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858”, Leukemia, 2017, 27 pages.
[cited by applicant]
Kuang et al., “Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1”, The Journal of Experimental Medicine, vol. 206, No. 6, pp. 1327-1337.
[cited by applicant]
Haynes et al., “Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcϵRI-γ”, The Journal of Immunology, 2001, vol. 166, pp. 182-187.
[cited by applicant]
Cartellieri et al., “Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer”, Journal of Biomedicine and Biotechnology, 2010, vol. 2010, No. 956304, pp. 1-13.
[cited by applicant]
Konstantinidis et al., “Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells”, Experimental Hematology, 2005, vol. 33, No. 2, pp. 159-164.
[cited by applicant]
Garcia-Sanchez et al., “Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologou…
[cited by applicant]
Stasi et al., “Inducible apoptosis as a safety switch for adoptive cell therapy”, The New England Journal of Medicine, 2011, vol. 365, No. 18, pp. 1673-1683.
[cited by applicant]
Morgan Richard A, “Live and let die: a new suicide gene therapy moves to the clinic”, Molecular Therapy, 2012, vol. 20, No. 1, pp. 11-13.
[cited by applicant]
Klingemann et al., “Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells”, Cancer Immunology, Immunotherapy, 1991, vol. 33, pp. 395-397.
[cited by applicant]
Genin et al., “M1 and M2 macrophages derived fromTHP-1 cells differentially modulate the response of cancer cells to etoposide”, BMC Cancer 2015, vol. 15, No. 577, pp. 1-14.
[cited by applicant]
Lu et al., “The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells”, The Journal of Immunology, 2017, vol. 198 (1 Supplement) 124.9, 5 pages.
[cited by applicant]
Touati et al., “A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response”, Current Gene Therapy, vol. 14, No. 3, 1page.
[cited by applicant]
Notice of Acceptance received for Australian Patent Application Serial No. 2019370094 dated Jan. 20, 2022, 3 pages.
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3094111 dated Sep. 27, 2021, 4 pages.
[cited by applicant]